Avian Influenza Virus Type A H9N2 subtype antibody and antigen (recombinant protein)
Diagnostic anti-Avian Influenza Virus Type A H9N2 subtype antibodies pairs and antigen for animal health (animal Avian/Bird/Poultry infectious disease Avian influenza) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Avian/Bird/Poultry disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-VT-P215-Ag01 | Recombinant Avian Influenza Virus Type A H9N2 subtype protein | $3090.00 |
GMP-VT-P215-Ab01 | Anti-Avian Influenza Virus Type A H9N2 subtype mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P215-Ab02 | Anti-Avian Influenza Virus Type A H9N2 subtype mouse monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-VT-P215-Ag01 |
Product Name | Recombinant Avian Influenza Virus Type A H9N2 subtype protein |
Pathogen | Avian Influenza Virus Type A H9N2 subtype |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Avian Influenza Virus Type A H9N2 subtype antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Avian Influenza Virus Type A H9N2 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Tag | His | Product description | Recombinant Avian Influenza Virus Type A H9N2 subtype proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P215-Ab01,GMP-VT-P215-Ab02 |
Pathogen | Avian Influenza Virus Type A H9N2 subtype |
Product Name | Anti-Avian Influenza Virus Type A H9N2 subtype mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Avian Influenza Virus Type A H9N2 subtype antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A H9N2 subtype antibodies in Avian Influenza Virus Type A H9N2 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Product description | Anti-Avian Influenza Virus Type A H9N2 subtype mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A H9N2 subtype antibodies./td> |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Pathogen
H9N2 avian influenza virus is an orthomyxovirus that belongs to the family Orthomyxoviridae. The virus has a spherical shape and is enveloped, with a segmented genome consisting of eight RNA segments that encode for the different viral proteins. The viral proteins include polymerase basic protein 2 (PB2), polymerase basic protein 1 (PB1), polymerase acidic protein (PA), hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), and matrix protein (M). These proteins are critical for the replication and transmission of the virus, as well as its pathogenicity.
H9N2 avian influenza virus primarily infects birds, such as domestic poultry, but it can also infect humans and other mammals, including pigs and dogs. In birds, H9N2 infection can cause respiratory distress, decreased egg production, and even death. However, the virus can be asymptomatic in some bird species, making it challenging to detect and control. In humans, H9N2 infection usually results in mild upper respiratory symptoms, such as fever, cough, and sore throat. However, in rare cases, the virus can lead to severe respiratory complications, such as pneumonia.
The transmission of H9N2 avian influenza virus occurs mainly through contact with infected birds or their secretions, such as feces, nasal secretions, and saliva. The virus can also be transmitted through contaminated surfaces and objects. Human-to-human transmission of H9N2 avian influenza virus is rare and limited to close contact with infected individuals. However, the virus's ability to infect humans and other mammals raises concerns about the potential for viral reassortment and the emergence of novel influenza viruses with pandemic potential.
The diagnosis of H9N2 avian influenza virus can be challenging, as the symptoms in birds are non-specific, and the virus can remain asymptomatic in some bird species. The most common diagnostic tests for H9N2 avian influenza virus include nucleic acid-based tests, such as RT-PCR and qRT-PCR, which target the virus's specific gene segments. These tests can detect the virus in various clinical samples, such as nasal swabs, feces, and blood. Serological tests, such as ELISA, can also be used to detect antibodies against the virus in suspected cases of infection.
The prevention and control of H9N2 avian influenza virus depend on implementing effective biosecurity measures, such as strict sanitation practices, quarantining of infected birds, and culling infected flocks. Additionally, vaccination programs in poultry populations can reduce the spread of the virus and limit its transmission to humans. In humans, antiviral medications, such as neuraminidase inhibitors, can be effective in treating H9N2 avian influenza virus infections, but their effectiveness is dependent on early diagnosis and prompt treatment.
In conclusion, H9N2 avian influenza virus is an important zoonotic pathogen that infects birds, humans, and other mammals. The virus's ability to infect multiple species and the risk of viral reassortment underscore the importance of effective surveillance and control measures to prevent the emergence of novel influenza viruses with pandemic potential.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.